Compositions comprising a chemokine receptor pathway inhibitor
AssigneeDimerix Bioscience Pty Ltd.
InventorsBronwyn Jane POLLOCK, Robert SHEPHERD, Nina WEBSTER
Life of this patent
Estimating the term…
Abstract
A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium: ii. a diluent in a concentration from 30 to 70% w/w; iii. a binder in a concentration from 2 to 5% w/w: iv. a disintegrant in a concentration from 2 to 8% w/w; and v. a lubricant in a concentration from 0.05 to 5% w/w; and methods of treatment with same.
Claims25
A composition comprising:
- i at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof;
- ii. a diluent in a concentration from 30 to 70% w/w;
- iii. a binder in a concentration from 2 to 5% w/w;
- iv. a disintegrant in a concentration from 2 to 8% w/w;
- and
- V. a lubricant in a concentration from 0.05 to 5% w/w.
A method for the treatment, amelioration or prevention of a condition or disease comprising administering to said subject a therapeutically effective amount of:
- a) a composition comprising
- i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof;
- ii. a diluent in a concentration from 30 to 70% w/w;
- iii. a binder in a concentration from 2 to 5% w/w;
- iv. a disintegrant in a concentration from 2 to 8% w/w;
- and
- v. a lubricant in a concentration from 0.05 to 5% w/w.
(canceled)
(canceled)
A composition comprising:
- i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof;
- ii. a diluent that is silicified microcrystalline cellulose (SMCC) in a concentration from 30 to 70% w/w;
- iii. a binder that is hypromellose (HPMC) in a concentration from 2 to 5% w/w;
- iv. a disintegrant that is sodium starch glycolate in a concentration from 2 to 8% w/w;
- and
- V. a lubricant that is magnesium stearate in a concentration from 0.05 to 5% w/w.
Dependencies are inferred from the claim text.